Clinical trial · Interventional
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
NCT02199327CI-TRIAL-00028984completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the therapeutic efficacy of interferon alfa 2b and topical mitomycin C in patients with diagnosis of conjunctival-corneal intraepithelial neoplasia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Conjunctival Intraepithelial Neoplasia | Conjunctival Squamous Intraepithelial Neoplasia | ALIAS | 0.90 |
| Corneal Intraepithelial Neoplasia | Corneal Squamous Intraepithelial Neoplasia | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interferon Alfa-2b | Drug | Interferon Alfa-2b | ALIAS |
| Mitomycin C | Drug | Mitomycin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Mitomycin C
- description
- Mitomycin C 0.04% 4 times daily for 7 days and 7 days off until resolution of neoplasia (3-6 cycles).
- interventionNames
- Drug: Mitomycin C
- type
- ACTIVE_COMPARATOR
- label
- Interferon alfa 2b
- description
- Interferon alfa-2b 1 million IU/ml 4 times daily until complete resolution of the tumor
- interventionNames
- Drug: Interferon Alfa-2b
Primary outcomes (1)
- measure
- Therapeutic effect - 100% resolution- with interferon alfa-2b and mitomycin C in patients diagnosed with primary conjunctival-corneal intraepithelial neoplasia
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with clinical diagnosis of corneal and conjunctival intraepithelial neoplasia (CIN) with no history of ocular neoplasia Exclusion Criteria: * Patients who did not agree to participate in the study. * Patients with corneal abrasion * Patients who have the diagnosis of CIN, but are pregnant
References
Publications (0)
Data not yet available
No reference posted for this study.